A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI)
David Carrick, Keith G Oldroyd, Margaret McEntegart, Caroline Haig, Mark C Petrie, Hany Eteiba, Stuart Hood, Colum Owens, Stuart Watkins, Jamie Layland, Mitchell Lindsay, Eileen Peat, Alan Rae, Miles Behan, Arvind Sood, W Stewart Hillis, Ify Mordi, Ahmed Mahrous, Nadeem Ahmed, Rebekah Wilson, Laura Lasalle, Philippe Généreux, Ian Ford, Colin Berry, David Carrick, Keith G Oldroyd, Margaret McEntegart, Caroline Haig, Mark C Petrie, Hany Eteiba, Stuart Hood, Colum Owens, Stuart Watkins, Jamie Layland, Mitchell Lindsay, Eileen Peat, Alan Rae, Miles Behan, Arvind Sood, W Stewart Hillis, Ify Mordi, Ahmed Mahrous, Nadeem Ahmed, Rebekah Wilson, Laura Lasalle, Philippe Généreux, Ian Ford, Colin Berry
Abstract
Objectives: The aim of this study was to assess whether deferred stenting might reduce no-reflow and salvage myocardium in primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
Background: No-reflow is associated with adverse outcomes in STEMI.
Methods: This was a prospective, single-center, randomized, controlled, proof-of-concept trial in reperfused STEMI patients with ≥1 risk factors for no-reflow. Randomization was to deferred stenting with an intention-to-stent 4 to 16 h later or conventional treatment with immediate stenting. The primary outcome was the incidence of no-/slow-reflow (Thrombolysis In Myocardial Infarction ≤2). Cardiac magnetic resonance imaging was performed 2 days and 6 months after myocardial infarction. Myocardial salvage was the final infarct size indexed to the initial area at risk.
Results: Of 411 STEMI patients (March 11, 2012 to November 21, 2012), 101 patients (mean age, 60 years; 69% male) were randomized (52 to the deferred stenting group, 49 to the immediate stenting). The median (interquartile range [IQR]) time to the second procedure in the deferred stenting group was 9 h (IQR: 6 to 12 h). Fewer patients in the deferred stenting group had no-/slow-reflow (14 [29%] vs. 3 [6%]; p = 0.006), no reflow (7 [14%] vs. 1 [2%]; p = 0.052) and intraprocedural thrombotic events (16 [33%] vs. 5 [10%]; p = 0.010). Thrombolysis In Myocardial Infarction coronary flow grades at the end of PCI were higher in the deferred stenting group (p = 0.018). Recurrent STEMI occurred in 2 patients in the deferred stenting group before the second procedure. Myocardial salvage index at 6 months was greater in the deferred stenting group (68 [IQR: 54% to 82%] vs. 56 [IQR: 31% to 72%]; p = 0.031].
Conclusions: In high-risk STEMI patients, deferred stenting in primary PCI reduced no-reflow and increased myocardial salvage. (Deferred Stent Trial in STEMI; NCT01717573).
Keywords: deferred stenting; myocardial infarction; myocardial salvage; no-reflow; primary percutaneous coronary intervention.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Figures
References
- Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet. 2003;361:13–20.
- O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:485–510.
- Jaffe R., Charron T., Puley G., Dick A., Strauss B.H. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117:3152–3156.
- Morishima I., Sone T., Okumura K., et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36:1202–1209.
- Antoniucci D., Valenti R., Migliorini A., et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction. Am Heart J. 2001;142:684–690.
- Ndrepepa G., Tiroch K., Keta D., et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv. 2010;3:27–33.
- Harrison R.W., Aggarwal A., Ou F.S., et al. American College of Cardiology National Cardiovascular Data Registry Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013;111:178–184.
- Vijayalakshmi K., Whittaker V.J., Kunadian B., et al. Prospective, randomized, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278–1284.
- Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44–122.
- Berry C, Ford I, Tzemos N, Oldroyd KG. Cardiac magnetic resonance imaging: new pathological insights and their functional and clinical significance in ST elevation acute myocardial infarction. UK CRN 10601. Available at: ). Accessed December 3, 2013.
- The TIMI Study Group The Thrombolysis In Myocardial Infarction (TIMI) trial. N Engl J Med. 1985;31:932–936.
- Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–888.
- Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–130.
- McEntegart M.B., Kirtane A.J., Cristea E., et al. Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2012;59:1745–1751.
- Aldrich H.R., Wagner N.B., Boswick J., et al. Use of initial ST-segment deviation for prediction of final electrocardiographic size of acute myocardial infarcts. Am J Cardiol. 1988;61:749–753.
- Kramer C.M., Barkhausen J., Flamm S.D., Kim R.J., Nagel E., Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols Standardized cardiovascular magnetic resonance imaging (CMR) protocols, Society for Cardiovascular Magnetic Resonance: Board of Trustees Task Force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.
- Kellman P., Arai E., McVeigh E.R., Aletras A.H. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002;47:372–383.
- Berry C., Kellman P., Mancini C., et al. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. Circ Cardiovasc Imaging. 2010;3:527–535.
- Payne A.R., Berry C., Doolin O., et al. Microvascular resistance predicts myocardial salvage and remodeling in ST elevation myocardial infarction. J Am Heart Assoc. 2012;1:e002246.
- Giri S., Chung Y.C., Merchant A., et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56.
- Thygesen K., Alpert J.S., Jaffe A.S., et al. Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–1598.
- Srinivasan M., Rihal C., Holmes D.R., Prasad A. Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: impact on microvascular perfusion and outcomes. Circulation. 2009;119:1311–1319.
- Niccoli G., Burzotta F., Galiuto L., Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281–292.
- Holmes D.R., Jr., Holubkov R., Vlietstra R.E., et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol. 1988;12:1149–1155.
- Vlaar P.J., Svilaas T., van der Horst I.C., et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915–1920.
- Stone G.W., Maehara A., Witzenbichler B., et al. INFUSE-AMI Investigators Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817–1826.
- Stone G.W., Abizaid A., Silber S., et al. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: The MASTER Trial. J Am Coll Cardiol. 2012 Sep 28 [E-pub ahead of print]
- Isaaz K., Robin C., Cerisier A., et al. A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coron Artery Dis. 2006;17:261–269.
- Kelbæk H., Engstrøm T., Ahtarovski K.A., et al. Deferred stent implantation in patients with ST-segment elevation myocardial infarction: a pilot study. EuroIntervention. 2013;8:1126–1133.
- Escaned J., Echavarría-Pinto M., Gorgadze T., et al. Safety of lone thrombus aspiration without concomitant coronary stenting in selected patients with acute myocardial infarction. EuroIntervention. 2013;8:1149–1156.
- Freixa X., Belle L., Joseph L., et al. Immediate vs. delayed stenting in acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention. 2013;8:1207–1216.
Source: PubMed